- Home
- PCYO vs NYXH Comparison
PCYO vs NYXH Comparison
Compare PCYO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- NYXH
- Stock Information
- Founded
- PCYO 1976
- NYXH 2009
- Country
- PCYO United States
- NYXH Belgium
- Employees
- PCYO N/A
- NYXH N/A
- Industry
- PCYO Water Supply
- NYXH Medical/Dental Instruments
- Sector
- PCYO Utilities
- NYXH Health Care
- Exchange
- PCYO Nasdaq
- NYXH Nasdaq
- Market Cap
- PCYO 242.7M
- NYXH 290.9M
- IPO Year
- PCYO N/A
- NYXH 2021
- Fundamental
- Price
- PCYO $10.12
- NYXH $7.58
- Analyst Decision
- PCYO
- NYXH Strong Buy
- Analyst Count
- PCYO 0
- NYXH 4
- Target Price
- PCYO N/A
- NYXH $14.50
- AVG Volume (30 Days)
- PCYO 55.5K
- NYXH 33.5K
- Earning Date
- PCYO 07-09-2025
- NYXH 08-05-2025
- Dividend Yield
- PCYO N/A
- NYXH N/A
- EPS Growth
- PCYO 123.89
- NYXH N/A
- EPS
- PCYO 0.56
- NYXH N/A
- Revenue
- PCYO $27,447,000.00
- NYXH $4,716,818.00
- Revenue This Year
- PCYO N/A
- NYXH $323.07
- Revenue Next Year
- PCYO N/A
- NYXH $204.30
- P/E Ratio
- PCYO $18.07
- NYXH N/A
- Revenue Growth
- PCYO 40.36
- NYXH N/A
- 52 Week Low
- PCYO $9.49
- NYXH $5.55
- 52 Week High
- PCYO $14.63
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- PCYO 46.29
- NYXH 44.38
- Support Level
- PCYO $9.91
- NYXH $7.65
- Resistance Level
- PCYO $10.13
- NYXH $8.37
- Average True Range (ATR)
- PCYO 0.25
- NYXH 0.26
- MACD
- PCYO -0.03
- NYXH -0.04
- Stochastic Oscillator
- PCYO 22.94
- NYXH 18.56
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.